DGAP-News

MOLOGEN AG: Presentation on IMPACT study at ESMO Symposium on Immuno-Oncology - Seite 2

response rates and safety, as well as collection of immunological and
pharmacodynamic data.

About MGN1703
MGN1703 is an innovative DNA-based TLR-9 agonist developed by MOLOGEN. It
broadly activates the immune system against tumor-associated antigens (TAA)
which are released by cancer cells. Once activated by MGN1703, the immune
system is able to overcome its fatal tolerance toward cancer cells and
attacks them selectively. Due to this mechanism of action, MGN1703 can be
applied to different indications of cancer.

MOLOGEN AG
MOLOGEN AG is a biotechnology company specialized in the research and
clinical development of cancer immune therapies and DNA vaccines against
infectious diseases.

The cancer immune therapy MGN1703 is the company's lead product and
best-in-class TLR-9 agonist. It is currently developed for first-line
maintenance treatment of colorectal cancer (pivotal randomized trial) and
lung cancer (randomized controlled trial). A second clinical-stage product
is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A
phase I/II clinical study has already been completed successfully.

With unique, patented technologies and innovative products, MOLOGEN is
pioneering immune therapies.

MOLOGEN AG is a publicly listed company, headquartered in Berlin. The
shares (ISIN DE0006637200) are listed in the Prime Standard of the German
Stock Exchange.

www.mologen.com

Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V.
| DECHEMA - Society for chemical technology and biotechnology e.V. |
German industrial association of biotechnology (DIB) | Association for
the Promotion of Science and Humanities in Germany | Association of
German biotechnology companies (VBU) | Association of researching
manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical
industry e.V. (VCI)

MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of
MOLOGEN AG.

Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 86
Fax: +49 - 30 - 84 17 88 - 50
[e-mail]

Note about risk for future predictions
Certain information in this report contains forward-looking statements or
the corresponding statements with negation or versions deviating from this
or comparable terminology. These are described as forward-looking
statements. In addition, all of the information given here that refers to
planned or future results of business areas, key financial figures,